Effect of eptifibatide, a glycoprotein IIb/IIIa antagonist, among diabetic patients following coronary stenting: Results from ESPRIT

被引：0
|
作者：
Labinaz, M
Madan, M
McGuire, DK
Batchelor, W
Saucedo, J
Pacchiana, C
Kitt, MM
O'Shea, JC
Talley, DJ
Liu, H
Timmis, S
Tcheng, JE
机构：
[1] Univ Ottawa, Inst Heart, Ottawa, ON, Canada
[2] Sunnybrook Hosp, Toronto, ON, Canada
[3] Duke Univ, Durham, NC USA
[4] Univ Toronto, Toronto, ON, Canada
[5] Univ Arkansas, Med Ctr, Little Rock, AR 72204 USA
[6] Duke Clin Res Inst, Durham, NC USA
[7] Cor Therapeut, San Francisco, CA USA
[8] Univ Arkansas, Little Rock, AR 72204 USA
[9] Jackson Madison Hosp, Jackson, TN USA
[10] William Beaumont Hosp, Royal Oak, MI 48072 USA
来源：
CIRCULATION | 2000年 / 102卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3215
引用
收藏
页码：665 / +
页数：2
相关论文
共 50 条
  • [21] The Effect of Glycoprotein IIb/IIIa Receptor Inhibitor on the Microcirculation in Patients Undergoing High-Risk Coronary Stenting; A Prospective, Randomized Study
    Philip Wong
    Scott Harding
    Ignacio Inglessis
    C. Joon Choi
    Darren Walters
    Yuchiao Chang
    Giogio Gimelli
    Ik-Kyung Jang
    Journal of Thrombosis and Thrombolysis, 2003, 16 : 163 - 166
  • [22] Results of clinical trials of a novel glycoprotein IIb-IIIa antagonist framon in high-risk coronary angioplasty
    Mazurov, AV
    Pevzner, DV
    Staroverov, II
    Samko, AN
    Antonova, OA
    Ivanov, VA
    Abugov, SA
    Gontuar, MG
    Chestukhin, VV
    Vlasik, TN
    Ruda, MYA
    KARDIOLOGIYA, 2005, 45 (05) : 4 - 12
  • [23] Platelet glycoprotein IIb/IIIa inhibition using eptifibatide with primary coronary stenting for acute myocardial infarction: A 30-day follow-up study
    Kaul, U
    Gupta, RK
    Haridas, KK
    Ramesh, SS
    Seth, KK
    Singh, B
    Agarwal, R
    Yadave, RD
    Ghose, T
    Sapra, RR
    Bajaj, R
    Shahi, M
    Bhagwat, A
    Kumar, P
    Mathews, OP
    CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2002, 57 (04) : 497 - 503
  • [24] Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes
    Mark, DB
    Harrington, RA
    Lincoff, AM
    Califf, RM
    Nelson, CL
    Tsiatis, AA
    Buell, H
    Mahaffey, KW
    Davidson-Ray, L
    Topol, EJ
    CIRCULATION, 2000, 101 (04) : 366 - 371
  • [25] Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome - Results of the TIMI 12 trial
    Cannon, CP
    McCabe, CH
    Borzak, S
    Henry, TD
    Tischler, MD
    Mueller, HS
    Feldman, R
    Palmeri, ST
    Ault, K
    Hamilton, SA
    Rothman, JM
    Novotny, WF
    Braunwald, E
    CIRCULATION, 1998, 97 (04) : 340 - 349
  • [26] Robust benefit of glycoprotein IIb/IIIa inhibition with eptifibatide in patients undergoing stent percutaneous coronary intervention with positive cardiac markers at baseline.
    O'Shea, JC
    Lorenz, TJ
    Joseph, D
    Kitt, MM
    Greenberg, S
    Lui, H
    Cantor, W
    Cohen, E
    Tcheng, JE
    AMERICAN JOURNAL OF CARDIOLOGY, 2000, 86 (8A): : 13I - 14I
  • [27] Continued thromboxane A(2) formation despite administration of a platelet glycoprotein IIb/IIIa antagonist in patients undergoing coronary angioplasty
    Byrne, A
    Moran, N
    Maher, M
    Walsh, N
    Crean, P
    Fitzgerald, DJ
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1997, 17 (11) : 3224 - 3229
  • [28] Pharmacokinetics and pharmacodynamics of argatroban in combination with a platelet glycoprotein IIB/IIIA receptor antagonist in patients undergoing percutaneous coronary intervention
    Cox, DS
    Kleiman, NS
    Boyle, DA
    Aluri, J
    Parchman, LG
    Holdbrook, F
    Fossler, MJ
    JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 44 (09): : 981 - 990
  • [29] Angiographic variables predict increased risk for adverse ischernic events after coronary stenting with glycoprotein IIb/IIIa inhibition - Results from the TARGET Trial
    Ross, MJ
    Herrmann, HC
    Moliterno, DJ
    Blankenship, JC
    Demopoulos, L
    DiBattiste, PM
    Ellis, SG
    Ghazzal, Z
    Martin, JL
    White, J
    Topol, EJ
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 42 (06) : 981 - 988
  • [30] Evolution in the practice of primary angioplasty: Effect of adjunctive coronary stenting and glycoprotein IIb/IIIa inhibitors on long-term outcomes
    Kalaria, VG
    Chaudhary, I
    Jacobson, S
    Pomerantz, RM
    Cove, CJ
    Ling, FS
    Cutlip, DE
    CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2001, 54 (03) : 327 - 332
12345